Mallinckrodt to Present at the BMO Prescriptions for Success Healthcare Conference

Rhea-AI Summary

Mallinckrodt plc (NYSE: MNK), a biopharmaceutical company, will present at the BMO Prescriptions for Success Healthcare Conference on June 23, 2020, at 8:00 a.m. Eastern Time. CEO Mark Trudeau and CFO Bryan Reasons will engage in a fireside chat during the event. Investors can access the webcast via the company's investor relations page. A replay will be available post-conference. Mallinckrodt specializes in treating autoimmune and rare diseases, focusing on various therapeutic areas. For more details, visit www.mallinckrodt.com/investors.

STAINES-UPON-THAMES, United Kingdom, June 17, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, will present on Tuesday, June 23, 2020 at the BMO Prescriptions for Success Healthcare Conference. Mark Trudeau, President and Chief Executive Officer, and Bryan Reasons, Executive Vice President and Chief Financial Officer, will represent the company in a fireside chat at 8:00 a.m. Eastern Time. To access the webcast, please refer to the webcast link posted on our site at: http://www.mallinckrodt.com/investors.  A replay of the fireside chat will also be available following the meeting.

ABOUT MALLINCKRODT
Mallinckrodt is a global business consisting of multiple wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies. The company's Specialty Brands reportable segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. Its Specialty Generics reportable segment includes specialty generic drugs and active pharmaceutical ingredients. To learn more about Mallinckrodt, visit www.mallinckrodt.com.

Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission (SEC) disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.

CONTACTS
Investor Relations
Daniel J. Speciale, CPA
Vice President, Investor Relations and IRO
(314) 654-3638
daniel.speciale@mnk.com

Media Inquiries
Ron Bartlett
H+K Strategies
Senior Vice President
813-545-2399
ron.bartlett@hkstrategies.com

Mallinckrodt, the "M" brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. Other brands are trademarks of a Mallinckrodt company or their respective owners. ^© 2020 Mallinckrodt.  06/2020

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/mallinckrodt-to-present-at-the-bmo-prescriptions-for-success-healthcare-conference-301078292.html

SOURCE Mallinckrodt plc

FAQ

What is the date and time of Mallinckrodt's presentation at the BMO Healthcare Conference?

Mallinckrodt will present on June 23, 2020, at 8:00 a.m. Eastern Time.

Who will represent Mallinckrodt at the BMO Healthcare Conference?

Mark Trudeau, CEO, and Bryan Reasons, CFO, will represent Mallinckrodt.

How can I access the webcast of Mallinckrodt's presentation?

You can access the webcast through Mallinckrodt's investor relations page at www.mallinckrodt.com/investors.

Will there be a replay available for Mallinckrodt's conference presentation?

Yes, a replay of the fireside chat will be available after the event.

What sectors does Mallinckrodt focus on in their specialty products?

Mallinckrodt focuses on autoimmune and rare diseases, including neurology, rheumatology, and respiratory therapies.